Contact us

877-469-1TRM
424-208-8866

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Open-Label, Sequential, Ascending, Multi-Dose, Phase 1/2 Study of KW-2450 in Combination with Lapatinib and Letrozole in Subjects with Advacned or Metastatic Breast Cancer Whose Tumors Overexpress HER-2

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Metastatic Breast Cancer Overexpressing HER-2 KW-2450 I/II Closed